Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 15,090 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 15,090 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total value of $60,963.60. Following the transaction, the chief executive officer now directly owns 3,759,929 shares in the company, valued at approximately $15,190,113.16. This represents a 0.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ CKPT opened at $4.01 on Friday. The firm has a market capitalization of $195.82 million, a PE ratio of -2.18 and a beta of 1.21. Checkpoint Therapeutics, Inc. has a 1-year low of $1.38 and a 1-year high of $4.50. The business’s fifty day moving average price is $3.42 and its two-hundred day moving average price is $3.31.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.47). The company had revenue of $0.04 million for the quarter. Equities research analysts expect that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CKPT. Lake Street Capital restated a “hold” rating and set a $4.10 price objective (down from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. D. Boral Capital restated a “buy” rating and issued a $4.80 price target on shares of Checkpoint Therapeutics in a research report on Monday, March 31st. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th.

Institutional Investors Weigh In On Checkpoint Therapeutics

Hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC grew its holdings in Checkpoint Therapeutics by 157.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company’s stock worth $34,000 after buying an additional 6,486 shares in the last quarter. Ameriflex Group Inc. acquired a new position in Checkpoint Therapeutics during the 4th quarter worth $32,000. PUREfi Wealth LLC bought a new position in shares of Checkpoint Therapeutics in the fourth quarter worth $32,000. SBI Securities Co. Ltd. acquired a new position in shares of Checkpoint Therapeutics during the fourth quarter valued at $32,000. Finally, Stifel Financial Corp bought a new stake in shares of Checkpoint Therapeutics during the fourth quarter valued at about $32,000. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.